Restless legs syndrome and periodic limb movement disorders.

Ali-Mohammad Kamali, Mohammad Nami

Journal: Progress in brain research 2026;301():63-91

PMID: 42754326

Abstract

Clinical confusion around restless legs syndrome (RLS), periodic limb movements during sleep (PLMS), and periodic limb movement disorder (PLMD) usually begins with a familiar sequence: the patient sleeps badly, the sleep study shows leg movements, and the report starts to sound like the diagnosis. The labels need more separation than that. RLS is diagnosed clinically from the history: an urge to move, often with uncomfortable sensations, brought out by rest, eased by movement, and worse in the evening or at night. PLMS are scored motor events. PLMD is reserved for the smaller group in whom those events plausibly account for sleep disturbance or daytime impairment after RLS, sleep-disordered breathing, narcolepsy, REM sleep behavior disorder, drug effects, and other neurological or medical causes have been considered. Biology is not a tidy dopamine story. Iron handling in the brain remains one of the more reproducible findings, although ferritin and transferrin saturation are only rough clinical proxies for central iron. Dopaminergic, adenosinergic, glutamatergic, spinal, autonomic, and genetic findings each explain part of the syndrome. Large genetic datasets, quantitative imaging, home movement recording, automated PLMS scoring, and autonomic measures have widened the field. Their immediate value is uneven: some help with mechanisms, some with measurement, and only a few currently change treatment decisions. Management still begins at the bedside. A typical RLS history, an incidental PLMS index, and possible PLMD lead to different choices. Iron indices should be checked early, medication and respiratory triggers need to be addressed, and dopamine agonist escalation should be avoided when augmentation is suspected. Current treatment is more cautious than older dopamine-centered practice: iron repletion when indicated, alpha-2-delta ligands for many chronic persistent cases, specialist use of opioids for severe refractory disease, and a selective role for device-based therapy. The chapter follows that clinical order rather than treating leg movement as a single target.

Copyright © 2026. Published by Elsevier B.V.

Address: DANA Brain Health Institute, Iranian Neuroscience Society-Fars Branch, Shiraz, Iran; Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: [email protected].; Cognitive Neuroscience, Cognitive Neuroscience and Neuropsychology Unit, School of Health Sciences and Psychology, Canadian University Dubai, Dubai, United Arab Emirates; ResearchHub, Advanced Technology Research Council, Abu Dhabi, United Arab Emirates; Sleep Consortium, West Palm Beach, FL, United States.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.